At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...
Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...
As a biotech that's planning to go big on artificial intelligence (AI) for drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is a decidedly forward-thinking organization. Rather than simply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results